April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Direct and Indirect Resource Use and Costs Associated With Non-Infectious Non-Anterior Uveitis
Author Affiliations & Notes
  • Jennifer E Thorne
    Ophthalmology, Johns Hopkins Wilmer Eye Inst, Baltimore, MD
  • Namita Tundia
    AbbVie Inc., North Chicago, IL
  • Martha Skup
    AbbVie Inc., North Chicago, IL
  • Dendy Macaulay
    Analysis Group, Inc., New York, NY
  • Cindy Revol
    Analysis Group, Inc., New York, NY
  • Jingdong Chao
    AbbVie Inc., North Chicago, IL
  • Parvez Mulani
    AbbVie Inc., North Chicago, IL
  • Andrew D Dick
    University of Bristol, Bristol, United Kingdom
  • Footnotes
    Commercial Relationships Jennifer Thorne, AbbVie (C), Allergan (F), Gilead (C), NEI (F), NIAID (F), RPB (F), XOMA (C); Namita Tundia, AbbVie (E), AbbVie (I); Martha Skup, AbbVie (E), AbbVie (I); Dendy Macaulay, AbbVie (C), Analysis Group (E); Cindy Revol, AbbVie (C), Analysis Group (E); Jingdong Chao, AbbVie (E), AbbVie (I); Parvez Mulani, AbbVie (E), AbbVie (I); Andrew Dick, University of Bristol and Institute of Ophthalmology, UCL (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5320. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jennifer E Thorne, Namita Tundia, Martha Skup, Dendy Macaulay, Cindy Revol, Jingdong Chao, Parvez Mulani, Andrew D Dick; Direct and Indirect Resource Use and Costs Associated With Non-Infectious Non-Anterior Uveitis. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5320.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Non-infectious uveitis (NIU) can cause visual impairment and as a result may incur an extensive economic burden to society. We assessed direct (medical service and prescription drug) and indirect (work loss) resource use and costs of privately insured US employees with non-anterior NIU and compared them to matched controls.

 
Methods
 

Employees 18-64 years old with ≥2 visits for non-anterior NIU (intermediate-, posterior- or pan-uveitis: ICD-9: 360.12, 362.12, 362.18, 363.0x, 363.10-13, 363.15, 363.2x, 364.24) from January 1, 1998 to March 31, 2012 were identified in the OptumHealth claims database. Employees had continuous eligibility ≥6 months before (baseline period) and 1 year after (study period) a randomly selected non-anterior NIU diagnosis (index date). Non-anterior NIU patients (cases) were matched 1:1 by sex, age, region and index date to controls without a diagnosis of uveitis. Direct resource use and costs associated with inpatient stays; emergency department (ED), outpatient and ophthalmologist/optometrist visits; and prescription drugs were calculated. Indirect resource use and costs associated with work loss resulting from disability and medically-related absenteeism also were calculated. All costs were adjusted to 2012 US dollars (USD). Direct/indirect resource use and costs incurred during the study period were compared between the 2 cohorts using Wilcoxon signed-rank or McNemar tests. Multivariate regression assessed key cost differences between cases and controls, adjusting for baseline characteristics.

 
Results
 

705 cases and 705 matched controls met the selection criteria (mean age, 45 years; 62.6% men). Cases had a significantly (P<0.05) higher number of mean visits compared to controls: ED (0.4 vs 0.2) and outpatient (16.5 vs 7.6) visits during the study period. Cases also used more prescription drugs (7.8 vs 4.1) and had more mean disability (10.3 vs 4.6), medically related absenteeism (8.5 vs 3.8), and total work loss days (18.7 vs 8.4) than controls (all comparisons P<0.05). Total direct and indirect costs were higher in cases than in controls, both in unadjusted (Figures 1 and 2) and adjusted results.

 
Conclusions
 

Non-anterior NIU is associated with substantial direct and indirect costs. More effective therapies may reduce this economic burden.

     
Keywords: 557 inflammation • 745 uvea • 669 quality of life  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×